RxDoctor Payments Data

Aida Wakil, MD

Ophthalmology · Albany, NYNPI 1205878576

Payments from drug & device makers

$757in general payments, 2019–2025

Across 32 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$218
  • Glaukos Corporation$106
  • Tarsus Pharmaceuticals, Inc.$75
  • Amgen$68
  • Omeros Corporation$54
  • Biotissue Holdings Inc.$53
  • plus $183 from 7 others

What the payments were for

  • Food & beverage$72496%
  • Education$334%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$757 in reported general payments places this provider in the 40th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$195,658
Medicare patients
622
Services billed
1,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine100$121,191
Cyclosporine84$36,545
XiidraLifitegrast21$28,864
LumiganBimatoprost39$24,730
Loteprednol Etabonate80$20,700
Alphagan PBrimonidine Tartrate25$15,407
MieboPerfluorohexyloctane/Pf14$12,885
Timolol Maleate143$11,042
Prednisolone Acetate232$7,985
Travoprost43$7,341
LotemaxLoteprednol Etabonate12$5,325
Brinzolamide31$5,239
Brimonidine Tartrate85$5,067
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$4,316
Latanoprost195$3,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$35$161,327164 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$33$41,74935 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax$14$26,02592 claims
AlconSimbrinza$218$3,14113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →